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Abstract 
Background: Insect bite hypersensitivity (IBH) is an IgE-mediated dermatitis caused by bites of Culicoides spp., which 
occurs frequently in horses imported from Iceland to continental Europe. IBH does not occur in Iceland because 
Culicoides species that bite horses are not present. However, Simulium vittatum (S. vittatum) are found in Iceland. In 
Europe, blood basophils from IBH-affected horses release significantly more sulfidoleukotrienes (sLT) than those 
from healthy controls after in vitro stimulation with Culicoides nubeculosus (C. nubeculosus) and S. vittatum. Aims of 
the study were: (I) using the sLT release assay, to test if horses living in Iceland were sensitized to S. vittatum and (II) to 
determine in a longitudinal study in horses imported from Iceland to Switzerland whether the sLT release assay would 
allow to predict which horses would develop IBH.
Results: Horses in Iceland, even when living in high S. vittatum areas, were usually not sensitized to S. vittatum or C. 
nubeculosus. Incidence of IBH in the 145 horses from the longitudinal study was 51% and mean time until IBH devel-
oped was 2.5 ± 1 year. Before import and after the first summer following import, there were no significant differences 
in sLT release between the endpoint healthy (H) and IBH groups. After the 2nd summer, when the number of clinically 
affected horses increased in the endpoint IBH group, a significantly higher sLT release after stimulation with C. nubecu-
losus but not with S. vittatum was observed. After the 3rd and 4th summer, the endpoint IBH group had a significantly 
higher sLT release with C. nubeculosus and S. vittatum than the endpoint H group. Some of the horses that remained 
healthy became transiently positive in the sLT release assay upon stimulation of their peripheral blood leucocytes with 
C. nubeculosus.
Conclusions: Horses in Iceland are not sensitized to S. vittatum. In horses that develop IBH, sensitization to S. vittatum 
is secondary to sensitization to C. nubeculosus and probably a result of an immunological cross-reactivity. A sLT release 
assay cannot be used to predict which horses will develop IBH. A transient positive reaction in the sLT release assay 
observed in horses that remained healthy suggests that immunoregulatory mechanisms may control an initial sensiti-
zation of the healthy horses.
Keywords: Culicoides, Icelandic horses, Insect bite hypersensitivity, Simulium, Sulfidoleukotriene release assay
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Acta Veterinaria Scandinavica
*Correspondence:  eliane.marti@vetsuisse.unibe.ch 
†Sigurbjörg Torsteinsdottir and Stephan Scheidegger contributed equally 
to the study
2 Department of Clinical Research & VPH, Vetsuisse Faculty, University 
of Berne, Länggass-str 124, 3012 Bern, Switzerland
Full list of author information is available at the end of the article
Page 2 of 10Torsteinsdottir et al. Acta Vet Scand           (2018) 60:69 
Background
Insect bite hypersensitivity (IBH) in horses also known as 
summer eczema (SE), sweet-itch, Queensland itch, Kasen 
or Culicoides hypersensitivity, is a chronic, recurrent sea-
sonal dermatitis of horses caused by an allergic reaction 
to the bite of midges, Culicoides spp. (reviewed in [1]). 
IBH affected horses were also reported to react against 
other blood feeding insects like black flies (Simulium 
spp.), stable flies (Stomoxys calcitrans), mosquitoes and 
horseflies [2–4].
The geographic distribution of the disease typi-
cally correlates with the location of Culicoides spp. but 
because these are not present in Iceland, Icelandic horses 
do not develop Culicoides-associated IBH. However, the 
black fly Simulium vittatum (S. vittatum) is indigenous 
to Iceland [5] and can occur in high numbers during the 
summer period in some areas and has been shown to 
feed on horses (Fig.  1). Icelandic horses that have been 
exported to continental Europe are predisposed to IBH, 
as 50% or more develop IBH within 2 years of export, if 
living in a known habitat of the responsible insect [6], 
while in Icelandic horses born in Europe the prevalence 
of IBH is similar to other breeds (3–10%) [7–9]. While 
a genetic predisposition for IBH is well-documented for 
horses born in an environment where Culicoides spp. are 
present [10–12] and gene regions associated with IBH 
have been identified in various breeds [13, 14], a genetic 
basis for IBH in Icelandic horses imported from Iceland 
to Europe could not be established [6, 10]. The fact that 
these horses are not exposed to Culicoides spp. anti-
gens early in life, due to their absence in Iceland, is the 
most likely factor for the high prevalence of IBH in these 
horses after import [10].
Several studies have shown that IBH is an IgE-medi-
ated, type I hypersensitivity reaction [1]. Horses with 
IBH but only rarely healthy control horses, have serum 
IgE antibodies against salivary gland proteins of Culi-
coides spp. [15–20]. Furthermore, in vitro stimulation of 
peripheral blood leucocytes (PBL) with Culicoides spp. 
allergens leads to the release of histamine or sulphidoleu-
kotrienes (sLT) in IBH-affected but only rarely in healthy 
control horses [21–23]. The value of a sLT release assay, 
with Culicoides nubeculosus (C. nubeculosus) as aller-
gen, for in vitro diagnosis of IBH has been evaluated in 
a well characterised, large population of IBH-affected 
and healthy animals and was shown to have a sensitivity 
of 80% and a specificity of 97% [4]. This study had also 
shown that horses with IBH are often not only sensitized 
to C. nubeculosus but also to S. vittatum [4]. These horses 
also have IgE antibodies binding to salivary gland aller-
gens of both C. nubeculosus and S. vittatum [24] and at 
least one of the S. vittatum allergens is cross-reactive 
with the corresponding allergen from C. nubeculosus 
[25]. These findings raised the question whether horses 
living in Iceland could be sensitized to S. vittatum aller-
gens, as these black flies are present in Iceland and bite 
horses, and whether horses sensitized to black flies in Ice-
land would be more prone to develop IBH after importa-
tion to Culicoides-rich environments, like Switzerland.
The aims of our study were (I) to test whether horses 
living in Iceland were sensitized to S. vittatum allergens 
by using the in vitro sLT release test and (II) to determine 
Fig. 1 Simulium vittatum (black flies) in the ear of a horse in Iceland (a). Bleeding skin lesions (within red circle) caused by the Simulium bites in the 
ear of the same horse (b). The pictures were taken at the time of blood sampling in Iceland
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in a longitudinal study of horses imported from Iceland to 
Switzerland, whether the in vitro sLT release assay with 
C. nubeculosus and S. vittatum allergen extracts would 
allow any prediction whether horses would develop IBH.
Methods
Design of the study
Data was collected in the years 2000–2010 from 275 
horses of the Icelandic breed all born in Iceland, of which 
130 remained in Iceland and 145 were exported to Swit-
zerland. The exported horses were monitored at the end 
of every summer after import for occurrence of clini-
cal signs of IBH over a period of one to up to six sum-
mers. The horses classified as remaining healthy (H) 
had to have been exposed to Culicoides spp. for at least 
three summers. Seventy-two of the 145 imported horses 
arrived in winter (out of IBH season, defined as 1st of 
October until 31st of April) when the adult insects caus-
ing IBH are not present in Switzerland, while the remain-
ing 73 horses were imported during the IBH season. A 
clinical examination was performed once a year at the 
end of each summer, blood samples were taken and the 
clinical history was recorded. Furthermore, in 40 of these 
horses, clinical examination and blood sampling had 
already been performed in Iceland before export. At the 
end of the study the clinical status towards IBH (healthy/
IBH/unknown) was determined.
Horses
The group of horses remaining in Iceland consisted of 
91 males and 39 females with an average age of 9.5 years 
(range 3–25 years). Out of these 130 horses, 76 were from 
infested black fly areas and 54 from areas with low expo-
sure. The group of exported horses (n = 145) consisted of 
111 males and 34 females. After import the horses lived 
in many different stables with other Icelandic horses in 
Switzerland. The age of the horses at the time of export 
was 4–12 years.
All horses were classified at the end of each IBH sea-
son as IBH-affected, not affected with IBH (healthy) or 
unknown diagnosis when the clinical signs and history 
did not allow a determination of whether the horse had 
IBH or not. This was for example the case when horses 
had mild pruritus and were immediately treated locally 
with repellents or anti-inflammatory ointments and thus 
had no clinical signs of IBH at the time of examination.
IBH-affected horses had pruritus with scratching and 
scaling, excoriations and thickening of the skin along 
the dorsal midline, mainly at the base of the mane and 
tail. Sometimes the ventral midline and/or the head were 
affected too. When clinical signs occurred for the first 
time, the diagnosis was confirmed retrospectively after 
remission of clinical signs in winter and recurrence of the 
disease the next summer. Following clinical diagnosis of 
IBH all horses received a wide variety of treatments such 
as sweet itch blankets, local application of various lotions 
for insect and pruritus control and in few cases systemic 
application of the corticosteroid triamcinoloni acedoni-
dum  (Kenacort®). Some of the IBH-affected horses were 
kept in the stable most of the day or were not allowed 
access to pasture during the IBH season.
The H horses had no clinical signs of scratching or 
skin alteration and were not treated against IBH. After 
import, all horses were vaccinated against tetanus and 
equine influenza and dewormed regularly.
Blood samples
Blood samples from the horses remaining in Iceland were 
obtained in August, when S. vittatum are active in Ice-
land. The horses in Switzerland were sampled at the end 
of each summer and 40 of them also before export. Sam-
pling was done by jugular venipuncture into ACD-B vac-
uette tubes (Greiner Bio-One vacuette GmbH, St-Gallen, 
Switzerland). Blood samples were kept at 10–25  °C and 
the sLT release assay (see below) performed within 24 h.
Clinical endpoint
The horses remaining in Iceland had no clinical signs of 
IBH.
Horses exported to Switzerland and assigned to the H 
endpoint group had not shown clinical signs of IBH at 
any time of the follow up study and had to be free of IBH 
at least three summers after import from Iceland, even 
though living in an environment where IBH-affected 
horses were living (i.e. as marker for the presence of Culi-
coides spp.). These horses had not been subjected to pro-
phylactic treatments against IBH (for example blankets 
etc.).
In 21 horses the clinical outcome was not clear enough 
to assign them to the healthy or IBH-endpoint group. 
This was the case when they were treated against IBH 
(blanket, repellents, etc.) as soon as they were slightly 
itchy or had crusts at the base of the mane and tail and 
the owners did not want to stop this treatment to see 
whether clinical signs of IBH would develop.
Horses assigned to the IBH endpoint group had shown 
the typical clinical signs of IBH, which recurred the next 
summer after remission in winter.
In vitro sulfidoleukotriene (sLT) release assay
The Equine  CAST® (Cellular Antigen Stimulation Test; 
Bühlmann Laboratories AG Schönenbuch, Switzerland) 
was performed as previously described [4]. Briefly: aller-
gen extracts were made from frozen insects (whole body) 
[21]. C. nubeculosus were laboratory bred, while S. vit-
tatum had been collected in Iceland. The C. nubeculosus 
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extract was used at a final concentration of 2 μg/mL and 
the S. vittatum extract was used at a final concentration 
of 10 μg/mL [4].
The leukocyte rich plasma from the blood samples 
was collected, transferred into a tube and centrifuged at 
130×g for 10 min at RT. The supernatant containing 90% 
of the platelets was removed and the pelleted cells were 
resuspended in 1 mL stimulation buffer (Bühlmann Lab-
oratories AG) per 9 mL of ACD-B anticoagulated blood. 
Cell stimulation was performed following the manufac-
turer’s instruction, either without stimulation to deter-
mine the spontaneous sLT release, or stimulation with 
Concanavalin A (20  μg/mL) as a control or with the C. 
nubeculosus and S. vittatum extracts. After 40 min incu-
bation at 37 °C the supernatants were removed and kept 
frozen for maximum 1  month until further processing. 
sLT determination was carried out following the manu-
facturer’s instructions using the Equine  CAST® ELISA 
(Bühlmann Laboratories AG). For all further evalua-
tions the values of the net stimulation were used, i.e. 
the spontaneous sLT release was subtracted from the 
values obtained with Concanavalin A or with the aller-
gen extracts. Horses with sLT release < 250  pg/mL with 
Concanavalin A were classified as ‘non responders’ (NR) 
[4, 21]. In the 1st year, 6 out of the 126 horses tested in 
the  CAST® were classified as NR, in the 2nd year 2 out of 
111, in the 3rd year 6 out of 85 and in the 4th year, 9 out 
of 60. The CAST results with the insect extracts of NR 
horses were not included in the statistical analyses.
To distinguish between positive or negative test results 
the cut-off values determined previously [4] were used. 
For the C. nubeculosus stimulation, the cut-off was 
310 pg/mL and for S. vittatum 200 pg/mL.
Statistical analyses
Statistical analyses were carried out with the statisti-
cal software package NCSS 2011 (NCSS, Kaysville, Utah 
84037, USA). A preliminary analysis indicated that the 
releases of sLT (pg/mL) were not distributed normally, 
even after logarithmic transformation. Medians and 
ranges were used subsequently for descriptive purposes.
To compare sLT release in the horses in Iceland living 
in a high or a low Simulium infested area, a Mann–Whit-
ney U-test was performed.
With the 112 horses in Switzerland with a clear clinical 
endpoint (H or IBH) at the end of the study, we analyzed 
whether gender and season of import (2-tailed Fisher’s 
exact test), age at import, and number of summers and 
months until the horses developed IBH (two sample 
T-test) were associated with clinical disease.
The nonparametric Mann–Whitney U-test was used 
to compare continuous variables such as released sLT 
after stimulation with Concanavalin A, S. vittatum or 
C. nubeculosus whole body extract in IBH-affected and 
healthy horses.
To compare binary variables such as number of IBH-
affected and healthy horses with sLT levels above or 
below the cut-offs defined above, the 2-tailed Fisher’s 
exact test was used.
The clinical diagnosis and CAST results with the insect 
extracts were available at all time points over a period of 
at least four summers in 29 endpoint H and 27 endpoint 
IBH horses. In order to investigate whether the CAST 
with the allergen extracts would allow identification of 
IBH prone horses before they develop clinical signs of 
the disease, the data were analyzed as follows: The sum-
mer when IBH-affected horses developed clinical signs of 
IBH for the first time was defined as T0 and the previ-
ous summers when the respective horses were exposed 
to insect bites but did not show clinical signs of IBH were 
set as T − 1, T − 2, T − 3 etc. The years following the first 
summer with IBH were defined as T + 1, T + 2 etc. In the 
horses that remained healthy until the end of the study, 
i.e. over four summers, T0 was defined as the last year of 
the study and T − 1, T − 2, T − 3 as the respective preced-
ing summers. The percentage of horses giving a positive 
test results with C. nubeculosus or S. vittatum antigen 
extracts at the different time points was then compared 
between the groups of horses that remained healthy or 
developed IBH. The two tailed Fisher’s exact test was 
used to determine whether there was a significant dif-
ference in the proportion of horses giving a positive test 
result between both groups.
Results
sLT release from C. nubeculosus and S. vittatum‑stimulated 
peripheral blood leukocytes of horses remaining in Iceland
From the 130 horses remaining in Iceland, two were NR 
and had thus to be removed from the analysis. Median 
sLT released after stimulation with C. nubeculosus and 
S. vittatum extracts were low and there were no sig-
nificant differences between the horses living in a low 
(n = 53) compared to those living in a high Simulium area 
(n = 75) (Table 1). Overall, only 3% of the horses gave a 
CAST results above the cut off after stimulation with S. 
vittatum extract and the values were low. Only one of the 
horses had a positive CAST results when stimulated with 
C. nubeculosus extract.
Development of clinical signs of IBH in horses imported 
from Iceland to Switzerland
Before export, the horses had, as expected, no clinical 
signs of the disease. After the 1st summer in Switzer-
land 92% of the 145 horses were classified as healthy, 
two horses were IBH-affected and 7% could not be clas-
sified as healthy or IBH-affected. One year later, 70% of 
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the 135 horses that could be followed were still healthy, 
14% had IBH and 16% could not be classified. After the 
third season in Switzerland, the percentage of horses 
that were free of IBH decreased to 50%, while 27% of the 
imported horses had IBH and 23% could not be classi-
fied. After the 4th season, the percentage of IBH-affected 
horses was higher (49%) than the percentage of healthy 
horses (40%). In the remaining 11% of the horses the clin-
ical diagnosis was unclear. In the last investigated period 
the percentages stayed virtually unchanged, with 43% 
IBH-affected, 39% healthy and 11% not classified horses 
(Fig. 2, Table 2). 
Factors influencing the clinical endpoint
From the 112 imported horses exposed for at least 
three summers to Culicoides spp., 55 horses (49%) had 
remained healthy and 57 (51%) had developed IBH. With 
these horses, we analyzed whether gender, age at import 
and season of import could influence the clinical end-
point. Furthermore, we also determined the mean num-
bers of summers and months following import until the 
horses developed IBH.
As shown in Table  3, the gender distribution was the 
same in the H and IBH endpoint groups, as in both the 
majority were males (76% and 77%, respectively). There 
were also no significant differences for the age at import 
as the horses from both groups had been imported into 
Switzerland at a mean age of 7.1 and 7.5  years, respec-
tively. Fifty-six percent of the 55 endpoint H horses 
had been imported during the IBH season and 44% out 
of the IBH season. Contrarily, the endpoint IBH horses 
were imported more frequently out of the IBH season 
(54%) than during the IBH season (46%), however, this 
Table 1 Sulfidoleukotriene (sLT) production by peripheral 
blood leucocytes (PBL) from  horses remaining in  Iceland 
in  areas with  low or  high infestation with  Simulium 
vittatum 
PBL were stimulated with C. nubeculosus extract (Cul2: 2 μg/mL) or S. vittatum 
extract (Sim10: 10 μg/mL)
The cut off values defined in Baselgia et al. [4] were used
Ns not significant
a One horse above cut off (310 pg/mL)
b, c Two horses in each group above cut off (200 pg/mL)
d Mann–Whitney U test
Incubation 
of PBL with
Median (range) of sLT released (pg/
mL) from PBL of horses coming 
from areas with
Low versus high
P
Low Simulium  
(N = 53)
High 
Simulium 
(N = 75)
(MWU‑testd)
Cul2 68 (0–925)a 74 (0–164) Ns
Sim10 6 (0–408)b 7 (0–391)c Ns
0
10
20
30
40
50
60
70
80
90
100
T1 T2 T3 T4 T5
%
 h
or
se
s
Number of summers following import from Iceland to Switzerland 
Fig. 2 Percentage of horses that over time developed IBH (pink line, squares), remained healthy (blue line, diamonds) or were classified with 
unclear clinical diagnosis (green line, triangles). The total number of horses included in the study at the different times is presented in Table 2. 
T1 − T4 corresponds to the number of summers spent in Switzerland after importation from Iceland to Switzerland, i.e. one (T1), two (T2), three (T3) 
and four (T4) summers after importation to Switzerland
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difference was not statistically significant. The horses 
developed IBH after a mean number of 2.8 ± 1 summers 
or 30  months after import and the endpoint H horses 
were followed in our study for a mean of 3.6 ± 0.8 sum-
mers or 39 months.
Time course of CAST results in relation to clinical endpoint
The median values of sLT (pg/mL) released after stimu-
lation with C. nubeculosus and S. vittatum extracts at 
the different time points in the endpoint IBH and end-
point H groups over the duration of the study are shown 
in Table  4. Of the 40 horses tested in Iceland and then 
exported, one was positive with the S. vittatum extract, 
but the sLT release was only slightly above the cut off 
(275  pg/mL). This horse developed IBH in Switzerland. 
sLT release was low in all other horses tested in Iceland 
and thus there were no significant differences in median 
sLT release with S. vittatum or C. nubeculosus between 
the endpoint H and endpoint IBH groups. The same was 
true the first summer after import. Nevertheless, at that 
time single horses (6%) gave positive CAST results with 
C. nubeculosus and even more frequently with S. vit-
tatum (20%). However, these differences were not statis-
tically significant (Fig. 3). After the second summer, with 
the increasing number of horses developing clinical signs 
of IBH (Fig.  2), the median sLT release with the insect 
extracts started to increase in the group with IBH as clin-
ical endpoint and became significantly different from the 
median of the H endpoint group for C. nubeculosus but 
not for S. vittatum extract (Table  4). These differences 
became even more pronounced after the third summer 
following import. Accordingly, after the second summer 
31% of the horses with IBH as a clinical endpoint gave a 
positive CAST result with C. nubeculosus versus only 7% 
of the H endpoint group (P < 0.01, Fig. 3a). This difference 
Table 2 Number of  horses involved in  the  longitudinal study before  export from  Iceland and  one (T − 1), two (T − 2), 
three (T − 3) and four (T − 4) summers after importation from Iceland into Switzerland
a At some time during the study
Iceland T1 T2 T3 T4 T5
Clinical status at time point 40 145 135 122 78 30
Tested in CAST
 Horses that remained healthy 15 71 55 41 19
 Horses that developed  IBHa 19 49 54 38 32
 Total 34 120 109 79 51
Table 3 Factors influencing the  clinical endpoint 
in  55 horses that  remained healthy (H) and  57 horses 
that developed insect bite hypersensitivity (IBH)
For this part of the study, only horses that had spent three or more summers in 
Switzerland were included in the healthy endpoint group
a Defined as time until diagnosis of IBH was first made or, in the healthy group, 
time point until which horses were monitored without showing clinical signs of 
IBH
Clinical endpoint Significance
H (n = 55) IBH 
(n = 57)
Fisher’s P 
(t‑test)
Gender (males:females) 42:13 44:13 Ns
Age at import (mean 
year ± SD)
7.1 ± 1.55 7.5 ± 1.61 Ns
Import during the IBH 
season (N/%)
31 (56%) 26 (46%) Ns
Import out of the IBH 
season (N/ %)
24 (44%) 31 (54%) Ns
Mean number ± SD of sum-
mers since import until 
clinical  outcomea
3.6 ± 0.8 2.8 ± 1 ≤ 0.001
Mean number ± SD of 
months since import until 
clinical  outcomea
39 ± 10 30 ± 12 ≤ 0.001
Table 4 Median (range) sLT release (pg/mL) after incubation 
of  peripheral blood leukocytes (PBL) with  C. nubeculosus 
extract (Cul2: 2 μg/mL) or S. vittatum extract (Sim10: 10 μg/
mL) from  horses that  remained healthy (H) or  developed 
insect bite hypersensitivity (IBH) at  different time points 
(see Table  2 for  number of  horses included at  each time 
point)
a Mann–Whitney U test
Time point Incubation 
of PBL with
Median (range) of sLT 
released (pg/mL) 
from horses with clinical 
endpoint
H versus IBH
P
H IBH (MWU‑testa)
Iceland Cul2 51 (0–109) 56 (0–109) Ns
Sim10 17 (0–91) 5 (0–275) Ns
T − 1 Cul2 51 (0–1291) 65 (0–2763) Ns
Sim10 26 (0–2251) 30 (0–2411) Ns
T − 2 Cul2 70 (0–3467) 100 (0–5900) < 0.01
Sim10 28 (0–4791) 85 (0–5350) < 0.1
T − 3 Cul2 60 (0–4855) 968 (0–4827) < 0.001
Sim10 100 (0–4745) 718 (0–11834) < 0.01
T − 4 Cul2 53 (0–4804) 244 (3–4798) < 0.0001
Sim10 53 (0–2402) 323 (0–4798) < 0.01
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increased after the third summer, with over 60% of the 
endpoint IBH horses giving a positive CAST result while 
the proportion of the endpoint H horses giving a posi-
tive test result with C. nubeculosus stayed at around 10% 
(Fig. 3a). A similar, although weaker difference was seen 
for the CAST with S. vittatum extract after the second 
(positive CAST in endpoint IBH group 41% versus 20% in 
endpoint H group; P < 0.05), and third summer (70% ver-
sus 44%, P < 0.05) following import (Fig. 3b). After the 4th 
summer the median sLT levels decreased in the H as well 
as in the IBH endpoint groups with both insect extracts 
(Table  4). Interestingly, within the H endpoint group 
there were hardly any horses that gave a positive test 
result with the C. nubeculosus extract, while about 60% of 
the endpoint IBH group were positive at that time point. 
The percentage of horses giving a positive test result also 
decreased with the S. vittatum extract, but there were 
still 30% of the horses in the H endpoint group that were 
positive with S. vittatum after the 4th summer.
Predictive value of the sLT release assay 
for the identification of IBH susceptible horses before first 
clinical signs of IBH
In order to assess if the CAST could allow to predict 
whether a horse would develop IBH before outbreak 
of the clinical signs, horses were grouped in those that 
developed IBH and those that remained healthy and the 
year when the first signs of IBH occurred was set as T0 
while the preceding years were set as T − 1, T − 2 etc.
Figure 4 shows that the CAST only allows the identifi-
cation of horses developing IBH in the season when the 
disease occurs, as it is the only time when the percentage 
of horses with IBH and with a positive test result either 
with C. nubeculosus or S. vittatum is significantly differ-
ent from the percentage of healthy horses positive in the 
CAST. At that time, 60% of the IBH horses but only 3.4% 
of the H horses are positive with C. nubeculosus. A vary-
ing proportion of horses was also positive in the CAST in 
the preceding years, however, a relatively high percentage 
0
10
20
30
40
50
60
70
80
Iceland T1 T2 T3 T4
%
 h
or
se
s 
po
si
tiv
e 
in
 th
e 
C
A
ST
**
***
***
0
10
20
30
40
50
60
70
80
Iceland T1 T2 T3 T4
%
 h
or
se
s 
po
si
tiv
e 
in
 th
e 
C
A
ST
*
*
Number of summers aer import to Switzerland 
a
b
Fig. 3 Longitudinal study of horses imported from Iceland to 
Switzerland. Percentage of clinical endpoint healthy (H, filled 
blue columns) or insect bite hypersensitivity (IBH, columns with 
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Fig. 4 Predictive value of the CAST for the identification of IBH 
susceptible horses before first clinical signs of IBH. Percentage of 
clinical endpoint healthy (N = 29; blue filled column) or IBH (N = 27; 
column with grey squares) horses that gave a positive CAST result 
with a Culicoides nubeculosus (2 μg/mL); or b Simulium vittatum 
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***P < 0.0001
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of the healthy group was also positive and the differences 
between both groups were not significant.
Discussion
Horses imported from Iceland to continental Europe 
represent a unique model to study the natural course of 
IBH because of the absence of Culicoides in Iceland and 
the high prevalence of this disease following import to 
an environment where Culicoides are present. One of the 
major difficulties of the study was that the horses were 
privately owned and living in different stables all over 
Switzerland. We tried to control for exposure to Culi-
coides spp. by only including horses living where expo-
sure to Culicoides spp. was known to occur, by using 
the presence of other IBH-affected horses. The sever-
ity of IBH was not evaluated because horses were often 
treated at first clinical signs. Severe IBH cases were thus 
rare. The horses in Iceland showed no clinical signs of 
IBH and after the first summer in Switzerland, only two 
confirmed cases of IBH out of the 145 horses were found. 
The prevalence then increased to up to 50% in the fourth 
summer following import, similarly to what has been 
found previously [6]. Although only 30% of the horses 
had a confirmed diagnosis of IBH after the third summer, 
we speculate that the real incidence was already higher 
at that time point because in 20% of the horses the diag-
nosis was not clear and thus only 50% of the horses were 
definitely free of IBH. The mean time until onset of IBH 
following import was 2.5 years and comparable to what 
has been described [6, 26]. In accordance with a previ-
ous study [8], the incidence of IBH was higher in horses 
imported out of the IBH season compared to import dur-
ing the IBH season but this difference was not statisti-
cally significant. Similarly to earlier publications [6, 8], we 
found no influence of gender or age at importation on the 
incidence of IBH. However, our study group only con-
sisted of Icelandic horses exported as adults (4–12 years). 
The incidence of IBH in Icelandic horses exported at 
young age (7–10 months) is much lower than if exported 
as adults and is similar to that of Icelandic horses born in 
Europe [27]. This might be explained by a higher capa-
bility of foals to make a regulatory immune response 
compared to adults [28]. The age at first exposure to Culi-
coides spp. appears thus to be an important predisposing 
factor [1, 27], while, unlike for horses born in Culicoides-
rich environments, genetic factors probably play a minor 
role [6, 10].
The CAST has been evaluated thoroughly for its use 
with C. nubeculosus and S. vittatum extracts to confirm 
a clinical diagnosis of IBH [4]. A high specificity (> 95%) 
of this test with C. nubeculosus extract with a sensitivity 
of 78% was found, while specificity and sensitivity were 
lower with S. vittatum extract. Our aim was to investigate 
whether Icelandic horses that would develop IBH follow-
ing exportation to Culicoides spp. areas would already be 
positive in CAST before the first onset of clinical signs 
and also, whether horses sensitized to S. vittatum in Ice-
land would be more prone to develop IBH after impor-
tation to Culicoides-rich environments. To establish the 
baseline values, 128 horses that remained in Iceland and 
40 horses from the follow up study were tested in the 
CAST in Iceland. Only one out of a total of 168 horses 
showed a positive test result with C. nubeculosus, con-
firming earlier studies [29, 30]. The results after stimu-
lation with S. vittatum are more interesting because S. 
vittatum are the only haematophagous flies that bite 
horses in Iceland [5]. The S. vittatum extract was made 
from S. vittatum captured from the wild in Iceland. 
However, only four of the 128 horses bled in the Simu-
lium season reacted to the extract and there were no 
differences between horses coming from high and low 
Simulium environment. From the 40 horses tested before 
export, only one was positive upon stimulation with S. 
vittatum. This horse, tested and exported at the end of 
summer, was positive in the CAST with both extracts a 
few months after arriving in Switzerland and developed 
clinical IBH the following summer. This suggests that 
the horse was already sensitized to S. vittatum allergens 
before export, but without clinical signs of IBH. In gen-
eral, Culicoides spp. allergens seem to be needed as sen-
sitizers whereas after sensitization many of the allergic 
horses cross-react to homologous proteins from Simu-
lium spp. Immunological cross-reactivity is a well-known 
phenomenon in allergy [31]. Homologous allergens found 
in Simulium spp. and Culicoides spp. that share common 
epitopes have been documented [19, 25, 32].
The percentage of horses showing a positive CAST 
with C. nubeculosus increased over time and got sig-
nificantly higher in the endpoint IBH compared to the 
H group after the second summer following import, 
reaching a peak after the third summer with 63% of the 
endpoint IBH and 12% of the endpoint H horses being 
positive. After the 4th summer the percentage of posi-
tive horses decreased to 50% in the endpoint IBH group, 
probably because most IBH-affected horses were treated, 
i.e. exposure to the allergens was strongly reduced. 
The results of the CAST could not be evaluated in all 
horses at all time points because blood samples were 
not always available and because of non-responders [4, 
21]. A complete data set over four summers was thus 
only available for 29 and 27 endpoint H and IBH horses, 
respectively. With these horses we investigated whether 
horses that developed IBH gave a positive CAST result 
in the years preceding first clinical signs. Twenty-six per-
cent and 20% of these horses were positive in the CAST 
with C. nubeculosus 1 and 2  years before clinical IBH, 
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respectively. Nevertheless, these results were not useful 
to identify IBH predisposed horses because 8–17% of the 
endpoint H horses were also positive in the test. How-
ever, most of the horses of the H endpoint group became 
negative in the following years, while 60% of the IBH 
group was positive in the CAST in the year when clini-
cal signs first occurred and this percentage increased to 
nearly 70% 1  year later (Fig.  4). At all time points there 
were more horses positive with S. vittatum than with 
C. nubeculosus and at T − 1 there were more endpoint 
H than IBH horses positive in CAST with this allergen. 
With both insect extracts a significant difference between 
the H and IBH endpoint group was thus only obtained 
when the horses become clinically affected with IBH. The 
proportion of healthy horses positive in the CAST with 
C. nubeculosus was higher than what was found previ-
ously in a study where only horses living for many years 
in Switzerland were included (17% versus < 5%; [4]). We 
do not know why a relatively high proportion of the H 
endpoint horses were positive in the CAST. Interestingly, 
most of them became CAST negative again later on. This 
suggests that a majority of horses become sensitized to 
these insects to some degree but that regulatory mecha-
nisms may then control sensitization [33, 34].
Conclusions
The major findings of this study are that 50% of Icelan-
dic horses imported from Iceland develop IBH follow-
ing import into Switzerland and that exposure to insect 
bites such as Culicoides spp. for at least one but usually 
for two to three summers is required to develop IBH. 
This indicates that horses in Iceland are not sensitized 
against Culicoides spp. or Simulium spp., although the 
latter are native to Iceland, a result that was confirmed 
by the CAST. Importantly, the present study shows 
that a positive CAST result when stimulating with C. 
nubeculosus in horses recently imported from Iceland 
can only be used to confirm clinical cases of IBH. The 
CAST should not be used to identify horses predis-
posed to IBH before occurrence of first clinical signs, 
because a part of the horses that remain free of this dis-
ease can be transiently positive in the test. This suggests 
that horses can be sensitized to Culicoides spp. aller-
gens to some degree but that regulatory mechanisms 
may then control further development of the disease.
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